Compare AG & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AG | ORKA |
|---|---|---|
| Founded | 1979 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 7.1B |
| IPO Year | 2004 | 1997 |
| Metric | AG | ORKA |
|---|---|---|
| Price | $19.86 | $91.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $21.92 | ★ $92.50 |
| AVG Volume (30 Days) | ★ 9.5M | 761.4K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.41 | N/A |
| Revenue Next Year | $10.68 | N/A |
| P/E Ratio | $143.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.04 | $14.67 |
| 52 Week High | $32.00 | $115.52 |
| Indicator | AG | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 55.54 | 40.35 |
| Support Level | $20.15 | $82.34 |
| Resistance Level | $21.27 | $95.02 |
| Average True Range (ATR) | 0.94 | 5.35 |
| MACD | -0.01 | -2.60 |
| Stochastic Oscillator | 45.87 | 20.19 |
First Majestic Silver Corp is in the business of production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. The company owns four producing mines in Mexico, consisting of the Santa Elena Silver/Gold Mine, the San Dimas Silver/Gold Mine, the Los Gatos Silver Mine, and the La Encantada Silver Mine. It also owns the Jerritt Canyon Gold Mine in Nevada, USA. Additionally, the firm holds interests in the San Martin Silver Mine and the Del Toro Silver Mine, and several exploration-stage projects. The majority of the company's revenues are from the sale of precious metals contained in dore and concentrate form. It generates maximum revenue from the sale of silver, followed by gold, zinc, copper, and other metals.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.